Marshall Wace, LLP Hille Vax, Inc. Transaction History
Marshall Wace, LLP
- $90.8 Billion
- Q3 2025
Shares
1 transactions
Others Institutions Holding HLVX
# of Institutions
7Shares Held
4.16MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY2.09MShares$4.37 Million0.0% of portfolio
-
Abingworth LLP London, X01.84MShares$3.84 Million10.2% of portfolio
-
Xtx Topco LTD London, X0179KShares$374,4940.02% of portfolio
-
Tekla Capital Management LLC27KShares$56,4290.02% of portfolio
-
Credit Suisse Ag Zurich, V815.7KShares$32,7870.0% of portfolio
About HilleVax, Inc.
- Ticker HLVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,427,200
- Market Cap $69.9M
- Description
- HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.